2026-04-18T07:26:22Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/102202024-12-13T09:46:38Zcom_2072_378071com_2072_378040col_2072_378097
RECERCAT
author
Baldirà, Jaume
author
Ruiz Sanmartin, Adolfo
author
Cortes, Alejandro
author
Angeles Sistac, Diego
author
Comas, Inma
author
Villena-Ortiz, Yolanda
author
Larrosa-Garcia, Maria
author
Ruiz-Rodriguez, Juan Carlos
author
Chiscano Camon, Luis
author
Ferrer Costa, Roser
author
González-López, Juan José
author
Ferrer, Ricard
2023-11-08T15:21:28Z
2023-11-08T15:21:28Z
2023-09-04T12:11:53Z2023-09-04T12:11:53Z2023-07-30
http://hdl.handle.net/11351/10220
Molecular diagnosis; Mortality; Sepsis biomarkersDiagnóstico molecular; Mortalidad; Biomarcadores de sepsisDiagnòstic molecular; Mortalitat; Biomarcadors de sèpsiaEarly diagnosis and appropriate treatments are crucial to reducing mortality risk in septic patients. Low SOFA scores and current biomarkers may not adequately discern patients that could develop severe organ dysfunction or have an elevated mortality risk. The aim of this prospective observational study was to evaluate the predictive value of the biomarkers mid-regional pro-adrenomedullin (MR-proADM), procalcitonin (PCT), C-reactive protein (CRP), and lactate for 28-day mortality in patients with sepsis, and patients with a SOFA score ≤6. 284 were included, with a 28-day all-cause mortality of 8.45% (n = 24). Non-survivors were older (p = 0.003), required mechanical ventilation (p = 0.04), were ventilated for longer (p = 0.02), and had higher APACHE II (p = 0.015) and SOFA (p = 0.027) scores. Lactate showed the highest predictive ability for all-cause 28-day mortality, with an area under the receiver-operating characteristic curve (AUROC) of 0.67 (0.55–0.79). The AUROC for all-cause 28-day mortality in patients with community-acquired infection was 0.69 (0.57–0.84) for SOFA and 0.70 (0.58–0.82) for MR-proADM. A 2.1 nmol/L cut-off point for this biomarker in this subgroup of patients discerned, with 100% sensibility, survivors from non-survivors at 28 days. In patients with community-acquired sepsis and initial SOFA score ≤ 6, MR-proADM could help identify patients at risk of 28-day mortality.This research was funded by a restricted grant from Thermo Fisher (Hennigsdorf, Germany), consisting of free-of-charge kits. However, the funding organization had no role in the collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Septicèmia - Diagnòstic
Marcadors bioquímics
Septicèmia - Mortalitat
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Early Diagnosis
CHEMICALS AND DRUGS::Biological Factors::Biomarkers
DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation::Systemic Inflammatory Response Syndrome::Sepsis
Other subheadings::Other subheadings::Other subheadings::Other subheadings::/mortality
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::diagnóstico precoz
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores
ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::inflamación::síndrome de respuesta inflamatoria sistémica::sepsis
Otros calificadores::Otros calificadores::Otros calificadores::Otros calificadores::/mortalidad
Use of Biomarkers to Improve 28-Day Mortality Stratification in Patients with Sepsis and SOFA ≤ 6
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion